Case Based Roundtable Logo

This roundtable series discusses the use of therapy after or instead of erythropoiesis-stimulating agents in patients with low- to intermediate-1 risk myelodysplastic syndromes, as discussed by key opinion leaders at virtual live events and interviews.

Therapies for MDS With Transfusion-Dependent Anemia

Dealing With Transfusion Dependence in Patients With MDS
Dealing With Transfusion Dependence in Patients With MDS
December 11, 2024
Abdulraheem Yacoub, MD, discusses option for patients with myelodysplastic syndromes and red blood cell transfusion dependence.
Patient Selection for Imetelstat Benefits From Considering AEs
Patient Selection for Imetelstat Benefits From Considering AEs
November 04, 2024
Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes.
Significance of New Therapeutic Options in MDS and Other Blood Cancers
Significance of New Therapeutic Options in MDS and Other Blood Cancers
October 15, 2024
Abdulraheem Yacoub, MD, discusses imetelstat as a newer and exciting option for patients with myelodysplastic syndromes.
Quality of Life Considered When Starting Treatment in MDS
Quality of Life Considered When Starting Treatment in MDS
September 06, 2024
Mikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.
Transfusion Independence Sustained With Imetelstat in Low-Risk MDS
Transfusion Independence Sustained With Imetelstat in Low-Risk MDS
August 26, 2024
Mikkael A. Sekeres MD, MS, discusses transfusion independence rates with imetelstat in patients with low- to intermediate-1 risk myelodysplastic syndromes.
A Deep Dive Into the FDA Approval of Imetelstat in Lower-Risk MDS
A Deep Dive Into the FDA Approval of Imetelstat in Lower-Risk MDS
July 01, 2024
Mikkael A. Sekeres MD, MS, further discussed the approval of imetelstat for the treatment of patients with low- to intermediate-1 risk myelodysplastic syndromes.